Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Angelo Baldassare Cefalu', Maurizio Averna, Paolo Calabrò, Diletta Arcidiacono, Laura D'Erasmo, Fabio Fimiani, Maria Giovanna Lupo, Nicola Ferri, Alice Zaramella, Alberto Zambon, Marcello Arca, Sara De Martin

Risultato della ricerca: Articlepeer review

Abstract

Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.
Lingua originaleEnglish
pagine (da-a)7-9
Numero di pagine3
RivistaAtherosclerosis Plus
Volume43
Stato di pubblicazionePublished - 2021

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2705???
  • ???subjectarea.asjc.2700.2724???

Fingerprint

Entra nei temi di ricerca di 'Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile'. Insieme formano una fingerprint unica.

Cita questo